Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5207907

COc1ccc2nc(C(N)=O)sc2c1.NCc1cccc(C(=O)N(CC(=O)O)c2ccccc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
CACNA1B Q00975 2/20 0.41
CACNA1H O95180 1/20 0.41
LMNA P02545 2/20 0.40
SCD O00767 4/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
F2 P00734 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
MAOB P27338 1/20 0.38
TP53 P04637 1/20 0.38
CSNK1D P48730 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5209105 0.90 TP53 (0.38) MAPTCACNA1BCACNA1HLMNAKDM4E
Trifluoroacetic Acid SCHEMBL5211180 0.89 NPC1 (0.39) MAPTLMNANPC1RAB9AF2
Trifluoroacetic Acid SCHEMBL5210737 0.88 F2 (0.38) MAPTCACNA1BCACNA1HMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5208921 0.87 PCSK9 (0.39) MAPTCACNA1BCACNA1HKDM4ENPC1
Trifluoroacetic Acid SCHEMBL5211772 0.86 RAD52 (0.41) MAPTLMNAKDM4EMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5208466 0.86 SMN1; SMN2 (0.41) MAPTLMNAMEN1KMT2ANPC1
SCHEMBL7432548 0.85 TP53 (0.41) MAPTLMNAKDM4EMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5208806 0.84 MAPT (0.37) MAPTLMNAKDM4EMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5205875 0.84 RAD52 (0.40) MAPTMEN1KMT2AF2TP53
SCHEMBL5207728 0.84 NPC1 (0.43) MAPTLMNAKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 EP disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed
EP-1240154-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2002-09-18 EP disclosed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 WO disclosed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 MAPT 4112/4885CACNA1B 4136/4885CACNA1H 3058/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 MAPT 4440/4885CACNA1B 3804/4885CACNA1H 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.